Related Experiment Video

Updated: Jan 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K

A New Era in the Management of Hypertrophic Cardiomyopathy

Ana Perez-Asensio1, Helena Llamas-Gomez2, Ana Lara-Palomo1

  • 1Cardiology Department, Hospital Universitario Puerta del Mar, 11007 Cadiz, Spain.

Reviews in Cardiovascular Medicine
|November 10, 2025
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) management is advancing with personalized treatments. New therapies target specific phenotypes, improving outcomes for heart failure, obstruction, and sudden cardiac death risk.

Area of Science:

  • Cardiology
  • Genetics
  • Medical Imaging

Background:

  • Hypertrophic cardiomyopathy (HCM) is a common heart condition with diverse presentations.
  • Phenotypic variability necessitates tailored treatment strategies.
  • Recent breakthroughs are revolutionizing HCM diagnosis and care.

Purpose of the Study:

  • To review recent advances in hypertrophic cardiomyopathy diagnosis and treatment.
  • To highlight novel therapeutic strategies for managing HCM phenotypes.
  • To discuss emerging gene-targeted therapies for HCM.

Main Methods:

  • Review of modern imaging techniques for risk stratification.
  • Analysis of myosin inhibitors for symptomatic obstructive HCM.
  • Evaluation of evolving invasive septal reduction techniques.
  • Exploration of gene replacement, editing, and silencing strategies.

Main Results:

  • Improved sudden cardiac death risk stratification using advanced imaging.
  • Myosin inhibitors offer a paradigm shift for obstructive HCM.
  • Novel invasive techniques enhance septal reduction.
  • Gene-targeted therapies show promise for future HCM management.

Conclusions:

  • Personalized medicine transforms hypertrophic cardiomyopathy care.
  • Advances in imaging, pharmacotherapy, and interventions improve patient outcomes.
  • Gene-targeted therapies represent a promising frontier in HCM treatment.

Keywords:
gene therapyhypertrophic cardiomyopathymyosin inhibitorsseptal reduction therapiessudden cardiac death risk stratification

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.8K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
323
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
305
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
207